BioSpace News Archive

The International Society for Heart and Lung Transplantation Academies have returned. The ISHLT Academies are standalone educational courses designed to improve and maintain the highest possible standards in the care of patients with advanced heart and lung disease.

Iridex Corporation, a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced the Company plans to participate in the upcoming Lytham Partners Fall 2021 Investor Conference.

Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced that Fred Guerard, PharmD, Chief Executive Officer of Graybug Vision, will participate in the following events at the Ophthalmology Innovation Summit (OIS) Retina on Thursday, October 7, 2021, in San Antonio, Texas.

Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that its partner Asahi Kasei Pharma Corporation (Asahi Kasei Pharma) has filed a New Drug Application (NDA) for the marketing authorization of isavuconazole (Cresemba ® ) in Japan for the treatment of the fungal infections aspergillosis, mucormycosis and cryptococcosis.

Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announce the participation of members of the company’s senior management in three investor and scientific conferences during October 2021.

Regeneron Pharmaceuticals, Inc. announced that a trial assessing investigational REGEN-COV™ in patients hospitalized with COVID-19 met its primary endpoint.

RELIEF THERAPEUTICS Holding SA announced that its wholly owned subsidiary, APR Applied Pharma Research SA, reported data published in the peer reviewed Journal of Wound Care, indicating that the company’s Nexodyn acid-oxidizing solution, developed with APR’s proprietary Tehclo technology, was found to be a highly effective treatment to support wound healing in infected or non-infected hard-to-heal leg ulcers.

RELIEF THERAPEUTICS Holding SA reported that the parent company of its U.S. collaboration partner, NRx Pharmaceuticals, Inc., has issued a press release providing a safety update on ZYESAMI /aviptadil) which is being tested in the ACTIV-3b/TESICO phase three study sponsored by the National Institutes of Health.

A rising need for expansion of healthcare access together with growth of the geriatric population unable to travel down to healthcare facilities is likely to play an important role in the development of the global remote patient monitoring market over the timeframe of analysis, from 2019 to 2029.

Kelyniam Global, a maker of custom cranial implants, is pleased to announce that the company has submitted all of the documentation required for establishment as a “Pink Current” filer under the new SEC Rule 15c2-11 ahead of schedule for the September 30, 2021 deadline.